Canadian Cardiovascular Society atrial fibrillation guidelines 2010: Management of recent-onset atrial fibrillation and flutter in the emergency department

Canadian Journal of Cardiology

Volumn 27, Issue 1, 2011, Pages 38-46

  Stiell, Ian G ^a   Macle, Laurent ^b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANADIAN CARDIOVASCULAR SOCIETY; COMORBIDITY; HEART ATRIUM FIBRILLATION; HUMAN; MEDICAL HISTORY; MEDICAL SOCIETY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; QUALITY OF LIFE; RISK ASSESSMENT; THROMBOEMBOLISM; AGED; CARDIOVERSION; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DRUG CONTRAINDICATION; EMERGENCY HEALTH SERVICE; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART ATRIUM FLUTTER; HEART PREEXCITATION; HEMODYNAMICS; PATHOPHYSIOLOGY; PATIENT REFERRAL; PHYSIOLOGY; RISK FACTOR; STROKE;

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT;

AGED; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; ELECTRIC COUNTERSHOCK; EMERGENCY SERVICE, HOSPITAL; EVIDENCE-BASED MEDICINE; FOLLOW-UP STUDIES; HEMODYNAMICS; HUMANS; PRE-EXCITATION SYNDROMES; REFERRAL AND CONSULTATION; RISK FACTORS; STROKE;

EID: 79953296523     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2010.11.014     Document Type: Article

References (64)

1. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. J Am Coll Card 2006;48:149-246.
2. Humphries KH, Jackevicius C, Gong Y, et al. Population rates of hospi-talization for atrial fibrillation/flutter in Canada. Can J Cardiol 2004;20: 869-76.
3. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitaliza-tion for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003;108:711-6.
4. Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003;14:666-72.
5. Krahn AD, Manfreda J,Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-84.
6. Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987;1:526-9.
7. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-8.
8. Heilbron B, Klein GJ, Talajic M, Guerra PG. 2004 Canadian Cardiovascular Society Consensus Conference: atrial fibrillation-management of atrial fibrillation in the emergency department and following acute myo-cardial infarction. Can J Cardiol 2005;21(Suppl B):61B-6B.
9. Skanes AC, Dorian P. 2004 Canadian Cardiovascular Society Consensus Conference: atrial fibrillation- etiology and initial investigation of atrial fibrillation. Can J Cardiol 2005;21(Suppl B):11B-4B.
10. Connors S, Dorian P. Management of supraventricular tachycardia in the emergency department. Can J Cardiol 1997;13 (Suppl A):19A-24A.
11. Michael JA, Stiell IG, Agarwal S, Mandavia DP. Cardioversion of paroxysmal atrial fibrillation in the emergency department. Ann Emerg Med 1999;33:379-87.
12. Wyse DG, Simpson CS. 2004 Canadian Cardiovascular Society Consensus Conference: atrial fibrillation-rate control versus rhythm control: decision making. Can J Cardiol 2005;21(Suppl B):15B-8B.
13. Page RL. Newly diagnosed atrial fibrillation. N Engl J Med 2004;351: 2408-16.
14. Hiatt WR, Lincoff M, Harrington RA. Acute pharmacological conversion of atrial fibrillation to sinus rhythm. Is short-term symptomatic therapy worth it? A report from the December 2007 Meeting of the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration. Circulation 2008;117:2956-7.
15. Taylor DM, AggarwallA,CarterM, Garewal D, HuntD. Management of new onset atrial fibrillation in previously well patients less than 60 years of age. Emerg Med Austral 2005;17:4-10.
16. Raghavan AV, Decker WW, Meloy TD. Management of atrial fibrillation in the emergency department. Emerg Med Clin N Am 2005;23:1127-39.
17. Burton JH, Vinson DR, Drummond K, et al. Electrical cardioversion of emergency department patients with atrial fibrillation. Ann Emerg Med 2004;44:20-30.
18. Stiell IG, Clement CM, Brison RJ, et al. Variation in management of recent-onset atrial fibrillation and flutter (RAFF) among academic hospital emergency departments. Ann Emerg Med 2010;57:13-21.
19. Borgundvaag B, Ovens H. Cardioversion of uncomplicated paroxysmal atrial fibrillation: a survey of practice by Canadian emergency physicians. Can J Emerg Med 2004;6:155-60.
20. Marx JA, Hockberger RS, Walls RW. Rosen's Emergency Medicine: concepts and clinical practice. 6th ed. St Louis: Mosby, 2006.
21. Wyse DG, Waldo AL, DiMarco JP, et al, for the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
22. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-77.
23. Decker WW, Smars PA, Vaidyanathan L,et al. A prospective, randomized trial of an emergency department observation unit for acute onset atrial fibrillation. Ann Emerg Med 2008;52:322-8.
24. Santini M, De Ferrari GM, Pandozi C, et al. Atrial fibrillation requiring urgent medical care. Approach and outcome in various departments of admission. Data from the Atrial Fibrillation/Flutter Italian Registry (FIRE). Ital Heart J 2004;5:205-13.
25. del Arco C, Martin A, Laguna P, Gargantilla P, for the Spanish Atrial Fibrillation in Emergency Medicince Study Group. Analysis of current management of atrial fibrillation in the acute setting: GEFAUR-1 study. Ann Emerg Med 2005;46:424-30.
26. Stiell IG, Clement CM, Perry JJ, et al. An aggressive protocol for rapid management and discharge of emergency department patients with recent-onset episodes of atrial fibrillation and flutter. Can J Emerg Med 2010;12:181-91.
27. Joseph AP, Ward MR. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone and digoxin for the reversion of new-onset atrial fibrillation. Ann Emerg Med 2000;36:1-9.
28. Domanovits H, Schillinger M, Thoennissen J, et al. Termination of recent-onset atrial fibrillation/flutter in the emergency department: a sequential approach with intravenous ibutilide and external electrical cardioversion. Resuscitation 2000;45:181-7.
29. Lemery R, Brugada P, Cheriex E, Wellens HJ. Reversibility of tachycardia-induced left ventricular dysfunction after closed-chest catheter ablation of the atrioventricular junction for intractable atrial fibrillation. Am J Cardiol 1987;60:1406-8.
30. Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967;29: 469-89.
31. Goldman M. The management of chronic atrial fibrillation: indications and method of conversion to sinus rhythm. Prof Cardiovasc Dis 1959;2: 465-79.
32. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):546S-52S.
33. Oral H, Ozaydin M, Sticherling C, et al. Effect of atrial fibrillation duration on probability of immediate recurrence after transthoracic cardioversion. J Cardiovasc Electrophysiol 2003;14:182-5.
34. Schwartzman D, Musley S, Koehler J, Warman E. Impact of atrial fibrillation duration on postcardioversion recurrence. Heart Rhythm 2005;2: 1324-9.
35. Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med 1994;331:785-91.
36. ACLS Guidelines: Part 7.3: Management of symptomatic bradycardia and tachycardia. Circulation 2005;112:IV-67-IV-77.
37. Nichol G, McAlister FA, Pham B, et al. Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart 2002;87:535-43.
38. Stiell IG, Clement C, Symington C, et al. Emergency department use of intravenous procainamide for patients with acute atrial fibrillation or flutter. Acad Emerg Med 2007;14:1158-64.
39. Blanc JF, De Ledinghen V, Trimoulet P, et al. Premalignant lesions and hepatocellular carcinoma in a non-cirrhotic alcoholic patient with iron overload and normal transferrin saturation. J Hepatol 1999;30:325-9.
40. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 2001; 37:542-7.
41. Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004;351:2384-91.
42. Hongo RH, Themistoclakis S, Raviele A, et al. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. J Am Coll Cardiol 2004;44:864-8.
43. Gowda RM, Khan IA, Wilbur SL, Vasavada BC, Sacchi TJ. Torsade de pointes: the clinical considerations. Int J Cardiol 2004;96:1-6.
44. Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, et al. Comparison of intravenous flecainide, propafenone and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000;86: 950-3.
45. Tijunelis MA, Herbert ME. Myth: intravenous amiodarone is safe in patients with atrial fibrillation and Wolff-Parkinson-White syndrome in the emergency department. Can J Emerg Med 2005;7:262-5.
46. Hilleman DE, Spinler SA. Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials. Pharmacotherapy 2002;22:66-74.
47. Chevalier P, Durand-Dubief A, Burri H, etal. Amiodarone versus placebo and classic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Card 2003;41:255-62.
48. Letelier LM, Udol K, Ena J, Weaver B, Guyatt GH. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. Arch Intern Med 2003;163:777-85.
49. Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharma-cologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract 2000;49:1033-46.
50. Roy D, Rowe BH, Stiell IG, et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004;44:2355-61.
51. Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation. A phase 3, randomized, placebo-controlled trial. Circulation 2008;117:1518-25.
52. Wyse DG. Initial energy for electrical cardioversion of atrial fibrillation: is more better? Am J Cardiol 2000;86:324-5.
53. de la Morandiere KP, Morriss H. Paddle position in emergency cardioversion of atrial fibrillation. Emerg Med J 2005;22:44-6.
54. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.
55. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham Heart Study. JAMA 2003;290:1049-56.
56. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and toler-ability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96.
57. Wyse DG. Bleeding while starting anticoagulation for thromboembolism prophylaxis in elderly patients with atrial fibrillation: from bad to worse. Circulation 2007;115:2684-6.
58. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
59. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103: 1116-27.
60. Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M, CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011; 27:74-90.
61. Nieuwlaat R, Dinh T, Olsson SB, et al. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur Heart J 2008;29:915-22.
62. Stramba-Badiale M. Atrial fibrillation subtypes, risk of stroke, and anti-thrombotic therapy. Eur Heart J 2008;29:840-2.
63. Klein AL, Grimm RA, Murray D, et al. Use of transesophageal echocar-diography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001;344:1411-20.
64. Manning WJ. Strategies for cardioversion of atrial fibrillation: time for a change? (Editorial). N Engl J Med 2001;344:1468-70.